AVIR
Price
$3.90
Change
+$0.16 (+4.28%)
Updated
Jul 25 closing price
Capitalization
333.76M
10 days until earnings call
XENE
Price
$30.30
Change
-$0.71 (-2.29%)
Updated
Jul 25 closing price
Capitalization
2.33B
11 days until earnings call
Interact to see
Advertisement

AVIR vs XENE

Header iconAVIR vs XENE Comparison
Open Charts AVIR vs XENEBanner chart's image
Atea Pharmaceuticals
Price$3.90
Change+$0.16 (+4.28%)
Volume$447.74K
Capitalization333.76M
Xenon Pharmaceuticals
Price$30.30
Change-$0.71 (-2.29%)
Volume$969.94K
Capitalization2.33B
AVIR vs XENE Comparison Chart in %
Loading...
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVIR vs. XENE commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVIR is a Buy and XENE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (AVIR: $3.90 vs. XENE: $30.30)
Brand notoriety: AVIR and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVIR: 116% vs. XENE: 83%
Market capitalization -- AVIR: $333.76M vs. XENE: $2.33B
AVIR [@Biotechnology] is valued at $333.76M. XENE’s [@Biotechnology] market capitalization is $2.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVIR’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • AVIR’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, both AVIR and XENE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVIR’s TA Score shows that 6 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • AVIR’s TA Score: 6 bullish, 3 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, AVIR is a better buy in the short-term than XENE.

Price Growth

AVIR (@Biotechnology) experienced а +16.07% price change this week, while XENE (@Biotechnology) price change was -4.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

AVIR is expected to report earnings on Nov 06, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($2.33B) has a higher market cap than AVIR($334M). AVIR YTD gains are higher at: 16.418 vs. XENE (-22.704). AVIR has higher annual earnings (EBITDA): -161.77M vs. XENE (-290.36M). XENE has more cash in the bank: 550M vs. AVIR (425M). AVIR has less debt than XENE: AVIR (1.45M) vs XENE (8.68M). XENE has higher revenues than AVIR: XENE (7.5M) vs AVIR (0).
AVIRXENEAVIR / XENE
Capitalization334M2.33B14%
EBITDA-161.77M-290.36M56%
Gain YTD16.418-22.704-72%
P/E RatioN/AN/A-
Revenue07.5M-
Total Cash425M550M77%
Total Debt1.45M8.68M17%
FUNDAMENTALS RATINGS
AVIR vs XENE: Fundamental Ratings
AVIR
XENE
OUTLOOK RATING
1..100
8086
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
9548
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
4486
P/E GROWTH RATING
1..100
955
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AVIR's Valuation (40) in the Biotechnology industry is somewhat better than the same rating for XENE (74). This means that AVIR’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (48) in the Biotechnology industry is somewhat better than the same rating for AVIR (95). This means that XENE’s stock grew somewhat faster than AVIR’s over the last 12 months.

XENE's SMR Rating (95) in the Biotechnology industry is in the same range as AVIR (95). This means that XENE’s stock grew similarly to AVIR’s over the last 12 months.

AVIR's Price Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for XENE (86). This means that AVIR’s stock grew somewhat faster than XENE’s over the last 12 months.

XENE's P/E Growth Rating (5) in the Biotechnology industry is significantly better than the same rating for AVIR (95). This means that XENE’s stock grew significantly faster than AVIR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AVIRXENE
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 10 days ago
72%
Declines
ODDS (%)
Bearish Trend 9 days ago
80%
Bearish Trend 2 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPSRX24.230.06
+0.25%
NYLI Epoch Global Equity Yield Class R6
BGITX15.270.03
+0.21%
Baillie Gifford International Alpha 2
VGHRX51.410.10
+0.19%
Voya Global High Dividend Low Vol R6
SIICX16.430.02
+0.12%
AlphaCentric Real Income C
DISVX28.38-0.04
-0.14%
DFA International Small Cap Value I

AVIR and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with AXON. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
+4.28%
AXON - AVIR
46%
Loosely correlated
+3.63%
XENE - AVIR
46%
Loosely correlated
-2.29%
IDYA - AVIR
44%
Loosely correlated
-1.33%
ZNTL - AVIR
43%
Loosely correlated
N/A
IMNM - AVIR
42%
Loosely correlated
-3.29%
More